Treatment of prostate disease with a nonsteroidal anti-androgeni

Details Treatment of prostate disease with a nonsteroidal anti-androgeni Treatment of prostate disease with a nonsteroidal anti-androgeni

1997-02-26

1999-02-16

Naff, David M.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Radical -xh acid, or anhydride, acid halide or salt thereof...

435 723, 435325, 435352, 435384, A61K 3116, G01N 33574, C12N 500

Patent

active

058721509

ABSTRACT:
An assay for identifying compounds with antiandrogenic activity employing a hamster ductus deferens cell line (DDT1) ATCC CRL-1701 and ATCC CRL-12051 is disclosed, as well as antiandrogenic compounds identified from this assay, particularly the nonsteroidal compound N-(4-chlorophenyl)-(Z,Z)-2,3-bis(cyclopropylmethylene)cyclopentane carboxamide of structural formula (I): ##STR1## This compound is an antiandrogen useful in the treatment and prevention of diseases of the prostate including prostatitis, benign prostatic hyperplasia (BPH) and prostatic carcinoma.

REFERENCES:
patent: 3953290 (1976-04-01), Uthne et al.
patent: 5130462 (1992-07-01), Slusarchyk
Marugo et al., J. Steroid Biochem. Molec. Biol., vol. 42, No. 5, pp. 547-554 (1992), "Effects of dihydrotestosterone and hydroxyflutamide on androgen receptors in cultured human breast cancer cells (EVSA-T)".
Lippman et al., Cancer Research, vol. 36, pp. 4610-4618 (1976), "The effects of androgens and antiandrogens on hormone-responsive human breast cancer in long-term tissue culture".
Norris et al., Nature, vol. 248, pp. 422-424 (1974), "Androgen receptors in a Syrian hamster ductus deferens tumour cell line".
Hori et al., J. of Antibiotics, vol. 46, No. 9, pp. 1327-1333 (1993), androgen-receptor antagonist produced by a Pseudomonas".
Wong, "Synthesis and some related studies of alkyl 2,3-bis(alkylidene)-cyclopentanecarboxylates", Ph.D. thesis, University of British Columbia, Dec., 1993.
Rasmusson et al., Ann. Rep. Med. Chem., vol. 29 (1994), pp. 225-234, "Therapeutic control of androgen action".
Tilley et al., Proc. Nat'l Acad. Sci. USA, vol. 86 (1989), pp. 327-331, "Characterization and expresion of a cDNA encoding the human androgen receptor".
Summerfield et al., Mol. Pharm., vol. 47 (1995), pp. 1080-1088, "Tissue-specific pharmacology of testosterone and 5alpha-dihydrotestosterone analogues . . . ".
Syms et al., J. Steroid Biochem., vol. 28 (1987), pp. 109-116, "Glucocorticoid effects on growth, and androgen receptor concentrations in DDT1MF-2 cell lines".
Harris et al., Molecular Endrocrinology, vol. 3 (1989), pp. 1839-1844, "Androgens and glucocorticoids modulate heparin-binding growth factor 1 mRNA accumulation in DDT1 cells as analyzed by in situ hybridization".
Smith et al., J. Steroid Biochem., "Differential Effects of Androgens and Glucocorticoids on Regulation . . . ", vol. 20, No. 1, pp. 277-281 (1984).
Smith et al., J. Steroid Biochem., "Steroid Regulation of Receptor Concentration and Oncogene Expression", vol. 24, No. 1, pp. 51-55 (1986).
Neri et al., Anticancer Research, "Complete Androgen Blockade as Treatment for Advanced Prostate Cancer . . . ", vol. 9, pp. 13-16 (1989).
Turcotte et al., J. Steroid Biochem, "Androgen Binding as Evidence by a Whole Cell Assay System . . . ", vol. 29, No. 1, pp. 69-76 (1988).
Toney et al., J. Steroid Biochem. Molec. Biol., "Non-steroidal L-245,976 Acts as a Classical Antiandrogen In Vivo", vol. 60, No. 1-2, pp. 131-136, 1997.

Affiliated with

Also associated with

Rating

Treatment of prostate disease with a nonsteroidal anti-androgeni does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treatment of prostate disease with a nonsteroidal anti-androgeni, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of prostate disease with a nonsteroidal anti-androgeni will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2062829